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ISSBACKGROUND Femoral access is the gold standard for transcatheter aortic valve replacement (TAVR). Guidelines
recommend reconsidering surgery when this access is not feasible. However, alternative peripheral accesses exist,
although they have not been accurately compared with femoral access.
OBJECTIVES This study compared nonfemoral peripheral (n-FP) TAVR with femoral TAVR.
METHODS Using the data from the national prospective French registry (FRANCE TAVI [French Transcatheter Aortic
Valve Implantation]), this study compared the characteristics and outcomes of TAVR procedures according to whether
they were performed through a femoral or a n-FP access, using a pre-speciﬁed propensity scorebased matching
between groups. Subanalysis during 2 study periods (2013 to 2015 and 2016 to 2017) and among low/intermediate-low
and intermediate-high/high volume centers were performed.
RESULTS Among 21,611 patients, 19,995 (92.5%) underwent femoral TAVR and 1,616 (7.5%) underwent n-FP TAVR
(transcarotid, n ¼ 914 or trans-subclavian, n ¼ 702). Patients in the n-FP access group had more severe disease (mean
logistic EuroSCORE 19.95 vs. 16.95; p < 0.001), with a higher rate of peripheral vascular disease, known coronary artery
disease, chronic pulmonary disease, and renal failure. After matching, there was no difference in the rate of post-
procedural death and complications according to access site, except for a 2-fold lower rate of major vascular compli-
cations (odds ratio: 0.45; 95% conﬁdence interval: 0.21 to 0.93; p ¼ 0.032) and unplanned vascular repairs (odds ratio:
0.41; 95% conﬁdence interval: 0.29 to 0.59; p < 0.001) in those who underwent n-FP access. The comparison of
outcomes provided similar results during the second study period and in intermediate-high/high volume centers.
CONCLUSIONS n-FP TAVR is associated with similar outcomes compared with femoral peripheral TAVR,
except for a 2-fold lower rate of major vascular complications and unplanned vascular repairs. n-FP TAVR may
be favored over surgery in patients who are deemed ineligible for femoral TAVR and may be a safe
alternative when femoral access risk is considered too high. (J Am Coll Cardiol 2019;74:2728–39)
© 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
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2729S ince its introduction in 2002, transcatheteraortic valve replacement (TAVR) has expandedrapidly as an alternative to surgical aortic valve
FP = femoral peripheral
CI = conﬁdence interval
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procedural risk (1–4).n-FP = nonfemoral peripheral
OR = odds ratio
PM = pacemaker
TAVR = transcatheter aortic
valve replacementFemoral peripheral (FP) access is the most studied
and widely used access for TAVR procedures; it al-
lows exclusive percutaneous intervention (5). How-
ever, despite the improvement in device proﬁles and
procedural techniques, FP access cannot be per-
formed in approximately 10% to 15% of patients due
to iliofemoral arteriopathy, tortuosity, severe calciﬁ-
cations, aortic aneurysm, mural thrombus, or previ-
ous vascular surgery (6). Current guidelines
recommend that surgery be reconsidered in patients
ineligible for FP access, mainly based on studies thatSEE PAGE 2740assessed the safety of transapical access (1,7). How-
ever, alternative nonfemoral peripheral (n-FP) ac-
cesses were recently developed (8–11). No randomized
trial has compared the outcome of TAVR according to
the access site, and observational studyderived
comparisons have been limited by the difference in
patient characteristics between the groups, with pa-
tients with more severe disease undergoing n-FP
TAVR. Although propensity-matched comparison of
transthoracic and FP TAVR has shown higher rates of
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Using data from the national prospective
French registry, the FRANCE TAVI (French
Transcatheter Aortic Valve Implantation)
registry, we compared 30-day outcomes of
TAVR procedures according to whether they
were performed through FP or n-FP access.
Outcomes were compared after propensity
scorebased matching of patients with FP and n-FP
interventions, with an assessment of temporal evo-
lution in practices and outcomes during 2 critical
periods (i.e., 2013 to 2015 and 2016 to 2017) and
among low/intermediate-low and intermediate-high/
high volume centers.
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2730Research and by the National Commission for Data
Protection and Liberties, whose principles are in line
with the General Data Protection Regulation. FRANCE
TAVI is registered with ClinicalTrials.gov (Registry of
Aortic Valve Bioprostheses Established by Cath-
eter; NCT01777828).
Designed as an all-comers registry, the FRANCE
TAVI registry prospectively includes all patients un-
dergoing TAVR procedures for severe aortic valve
stenosis in 50 active TAVR centers in France. The
decision to perform TAVR and the choices of access
site and prosthesis type are made by a multidisci-
plinary heart team in each participating center. Pro-
cedures and post-procedural management are
performed in accordance with the routine protocol of
each site. A 30-day follow-up is recommended in the
case report form and is performed either on site or by
telephone contact with the patient and the patient’s
physician according to the participating site prefer-
ence. Patients included in the registry provide writ-
ten informed consent for the procedure and for
anonymous processing of their data.
Data col lect ion . The FRANCE TAVI dataset is ﬁlled
through a dedicated web-based interface from the
French Society of Cardiology. Collected data include
baseline, procedural, and outcome characteristics.
The database is managed by the French Society of
Cardiology, which implements regular data quality
checks, including range checks and assessments of
internal consistency. In cases of missing, extreme, or
inconsistent values, centers are contacted and asked
to verify and modify the records as appropriate.
Outcomes are site-reported and standard deﬁni-
tions are used to enter the data. Major complications,
including valve migration or embolization, major
vascular complications, and bleeding were deﬁned
according to Valve Academic Research Consortium 2
criteria (14,15). Accordingly, major bleeding was
deﬁned as overt bleeding either associated with a
decrease in hemoglobin level of at least 3.0 g/dl or
requiring transfusion of at least 2 U of whole blood or
red blood cells, or bleeding that caused hospitaliza-
tion or permanent injury, or required surgery. Un-
planned vascular repair was deﬁned as any vascular
injury that led to unplanned surgery or stent im-
plantation. Renal failure was deﬁned as an at least 1.5
increase in serum creatinine level compared with
baseline or an increase of >0.3 mg/dl (26.4 mmol/l).
Study populat ion . Based on criteria speciﬁed by the
French Ministry of Health, patients included in the
registry were adults with severe aortic valve stenosis.
Severe aortic valve stenosis was diagnosed as deﬁned
by international guidelines. All patients enrolled in
the FRANCE TAVI registry between January 2, 2013and December 31, 2017 were included in the study.
Patients with missing data on valve type, access site,
or propensity score variables (Online Table 1) were
excluded from the analysis. The study ﬂowchart is
presented in Figure 1.
OPERATIVE TECHNIQUE. This was a multicentric
observational study in which each center used its own
technique. FP TAVR was percutaneous in most cases.
It was a surgical approach in all cases of n-FP TAVR.
The surgical cutdown of the trans-subclavian access
(including transaxillary or distal subclavian) was
performed through an infraclavicular incision
respecting the brachial plexus. In case of a carotid
approach, a 3- to 4-cm long, low cervical incision was
performed to expose the sternocleidomastoid muscle.
The jugular vein, the Vagus nerve, and the respiratory
tract were identiﬁed. Theoretically, the left access for
n-FP TAVR was often preferred over the right access
because it provided superior coaxial alignment with
the ascending aorta and optimal positioning of
the prosthesis.
Conscious sedation with local anesthesia or general
anesthesia was possible with all pathways.
ENDPOINTS. The primary endpoint for the pre-
speciﬁed propensity scorematching based compari-
son was procedural mortality (either in-hospital
mortality or 30-day mortality). Secondary endpoints
included all other in-hospital complications (Online
Table 2). Of note, 30-day follow-up was available in
all patients.
STATISTICAL ANALYSIS. This report was prepared in
compliance with the STROBE (Strengthening the
Reporting of Observational Studies in Epidemiology)
checklist for observational studies (16).
Baseline clinical characteristics were ﬁrst
described and compared between the 2 groups of in-
terest (FP TAVR vs. n-FP TAVR). Quantitative vari-
ables were presented as mean  SD (assumption of
normal distribution was assessed graphically using
histograms and QQ plots) and compared using
Student’s t-test. Categorical variables were presented
as numbers (percentages) and compared using the
chi-square test when appropriate (Fisher exact test
otherwise).
Among patients with peripheral TAVR (n ¼ 25,666),
baseline characteristics differences were considered
to be small because standardized differences
were <0.2 (median standardized difference was 0.05)
between those with a complete dataset (n ¼ 21,611)
versus those with $1 missing data (n ¼ 4,055), which
represented 14.5% of the overall population. We
performed an unadjusted comparison between n-FP
FIGURE 1 Study Flowchart
27,997 TAVR in the FRANCE TAVI Registry
between 2013 and 2017
OTHER or UNLABELED TAVR
n = 352
MISSING DATA
n = 352
CENTRAL TAVR
n = 1,979
PERIPHERAL VASCULAR
TAVR n = 25,666
PROPENSITY SCORE MATCHING
358 Low volume center
Matched NON-FEMORAL TAVR
358 Low volume center
Matched FEMORAL TAVR
1,246 High volume center
Matched NON-FEMORAL TAVR
1,246 High volume center
Matched FEMORAL TAVR
893 (2016-2017)
Matched NON-FEMORAL TAVR
893 (2016-2017)
Matched FEMORAL TAVR
720 (2013-2015)
Matched NON-FEMORAL TAVR
720 (2013-2015)
Matched FEMORAL TAVR
1,613 Total
Matched NON-FEMORAL TAVR
1,613 Total
Matched FEMORAL TAVR
21,611 PERIPHERAL VASCULAR TAVR
1,616 NON-FEMORAL
721 (2013–2015)
895 (2016–2017)
370 Low volume center
1,246 High volume center
9,062 (2013–2015)
10,933 (2016–2017)
5,101 Low volume center
14,894 High volume center
19,995 FEMORAL
Among 27,997 patients included in the FRANCE TAVI (French Transcatheter Aortic Valve Implantation) registry, 21,611 patients were included
in the study. Patients who underwent nonfemoral peripheral (n-FP) transcatheter aortic valve replacement (TAVR) (n ¼ 1,613) with complete
data were matched with 1,613 patients who underwent FP TAVR for comparison purposes.
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plete record to account for missing data.
Propensity scorebased matching was developed
using a logistic regression model that included 18 pre-
procedural variables known to be related to outcomes
and/or to the access site (regardless of their statistical
signiﬁcance, using a non-parsimonious approach) and
the center volume to abolish a possible “center ef-
fect.” The center volume was divided into 4 groups
using quartiles: low volume (#67 procedures per
year); low-intermediate volume (between 68 and 104
procedures per year); intermediate-high volume (be-
tween 105 and 155 procedures per year); and high
volume ($156 procedures per year). This model
allowed calculation of the probability (propensity
score) of n-FP TAVR access for each patient. Using the
propensity score, n-FP TAVR cases were matched to
FP TAVR cases. A nearest-neighbor 1:1 matching al-
gorithm on the basis of the propensity score was
applied, with a caliper width of 0.2 SD of the logit of
the propensity score. Standardized differences before
and after matching were estimated (with their 95%
conﬁdence interval [CI]) to assess the quality of the
propensity score matching procedure. A mirrored
histogram of distribution of propensity scores for n-
FP TAVR (bars below the zero line) versus FP TAVR
(bars above the zero line) is presented in Online
Figure 1.
Logistic regression models were used to estimate
the odds ratio (OR) of each endpoint for n-FP TAVR
access and adjusted for the type of prosthesis
implanted and the study period. The implanted
prosthesis type and the study period, which were
post-baseline covariates, were therefore not included
in the propensity score model and were taken into
account as possible confounding factors in the
multivariate regression model.
To further account for the evolution in catheter
size, device performance, and practices during the
study period, a ﬁrst subanalysis was performed with
a comparison of FP to n-FP TAVR in each study
period separately using the same methodology. A
second subanalysis was performed with a compari-
son of FP TAVR to n-FP TAVR in low/intermediate-
low volume centers and intermediate-high/high
volume centers separately using the same method-
ology. To ensure that the overall outcomes were not
driven by one compared with the other n-FP
approach, we performed an unadjusted comparison
between transcarotid and trans-subclavian
approaches.
All tests were 2-sided, and p values <0.05 were
considered to be statistically signiﬁcant. Statisticalanalyses were performed using R software version
3.4.1 (R Foundation, Vienna, Austria). The R package
MatchIt was used for the propensity scorebased
matching.
RESULTS
During the study period, 27,997 patients were
included in the FRANCE TAVI registry. Of those, 352
had missing data regarding the access site, 1,979 un-
derwent a central access (transapical or transaortic),
and 4,055 had at least 1 missing data among pro-
pensity score variables. Baselines characteristics and
impact of access type on the outcome of the un-
matched excluded population are presented in Online
Tables 3 and 4. Therefore, 21,611 patients underwent
peripheral vascular access and were included in the
study.
CHARACTERISTICS OF THE POPULATION BEFORE
MATCHING. FP access was used in 19,995 patients
(92.5%), whereas n-FP access was used in 1,616 cases
(7.5%). Baseline characteristics of the nonmatched
population are presented in Online Table 5.
Patients in the n-FP access group were younger
than those in the FP access group (81.83 years vs.
83.34 years; p < 0.001) and were more frequently men
(64.60% vs. 47.13%; p < 0.001). Patients in the n-FP
access group had more severe disease. Their mean
logistic EuroSCORE was higher (19.95 vs. 16.99;
p < 0.001), their ejection fractions were lower
(54.45% vs. 56.48%; p < 0.001), with higher rates of
known coronary artery disease (63.37% vs. 46.41%;
p < 0.001), previous cardiac surgery (21.78% vs.
13.06%; p < 0.001), diabetes mellitus (28.71% vs.
25.64%; p ¼ 0.007), renal failure (51.92% vs. 47.37%;
p < 0.001), peripheral vascular disease (50.25% vs.
18.69%; p < 0.001), and chronic pulmonary disease
(25.43% vs. 18.04%; p < 0.001).
Forest plots of patients’ factors associated with n-
FP TAVR versus factors associated with FP TAVR are
presented in Figure 2.
CHARACTERISTICS OF THE MATCHED POPULATION.
Baseline characteristics of the matched population
according to access type (n ¼ 1,613 in each group) are
shown in Table 1. In the n-FP access group, mean age
was 81.85 years versus 82.08 years in the FP group
(p ¼ 0.382), with 64.54% men versus 63.30% men
(p ¼ 0.453). A nonelective procedure was performed
in 8.31% of cases versus 8.68% of cases (p ¼ 0.705).
Stroke history was present in 12.09% of cases versus
13.64% of cases (p ¼ 0.189). Overall, patients’ char-
acteristics were similar for all variables included in
the propensity score. Balloon expandable prostheses
FIGURE 2 Patients’ Factors Associated With n-FP TAVR Versus FP TAVR
OR Lower CI Upper CI OR Plot (Log Scale)
General Characteristics
Age 0.97 0.97 0.98
Male 2.05 1.84 2.28
BMI (underweight) 1.38 1.06 1.76
BMI (overweight) 0.99 0.89 1.11
Logistic EuroSCORE 1.02 1.01 1.02
Indication (operative CI) 1.83 1.54 2.18
Indication (high surgical risk) 1.28 1.14 1.45
Indication (other) 1.59 1.24 2.03
Non-elective procedure 0.90 0.75 1.08
Extra Cardiac History
1.14 0.98 1.33
4.39 3.96 4.87
1.55 1.38 1.74
1.17 1.04 1.31
1.15 1.03 1.29
1.29 1.08 1.53
Previous stroke/TIA
Peripheral vascular disease
Chronic pulmonary disease
Diabetes mellitus
Renal failure (moderate)
Renal failure (severe)
Renal failure (dialysis) 1.73 1.23 2.37
Cardiac History
1.11 0.91 1.37
2.00 1.80 2.22
1.86 1.64 2.10
0.98 0.84 1.13
1.03 0.92 1.14
0.99 0.99 0.99
0.89 0.79 1.01
0.81 0.66 0.98
Cardiac symptoms
Coronary disease
Previous cardiac surgery
Previous permanent pacemaker
Previous SV arrhythmia
Ejection fraction
Pulmonary HT (moderate)
Pulmonary HT (severe)
Pulmonary HT (non-measurable
or non-available)
0.87 0.75 1.01
Aortic Valve Characteristics
0.99 0.99 0.99
1.40 1.1 1.75
1.09 1.07 1.11
Mean aortic gradient
Aortic valve area
Aortic annulus
Moderate or severe AR 1.13 0.99 1.29
Valve Type
Balloon-expandable 0.29 0.26 0.32
Center Size
1.33 1.06 1.68
0.99 0.80 1.25
Low-intermediate volume quartile
High-intermediate volume quartile
High volume quartile 1.63 1.33 2.01
Study Period
2016-2017 1.03 0.93 1.14
1 2 50.50.20.1
Odds ratios (ORs) expressing the probability of having n-FP TAVR. AR ¼ aortic regurgitation; BMI ¼ body mass index; CI ¼ conﬁdence interval; HT ¼ hypertension;
SV ¼ supraventricular; TIA ¼ transient ischemic attack; other abbreviations as in Figure 1.
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TABLE 1 Baseline Characteristics of the Total Matched Population According to the Access Type
Nonfemoral Access
(n ¼ 1,613)
Femoral Access
(n ¼ 1,613) p Value Standardized Difference
General characteristics
Age, yrs 81.85  7.31 82.08  7.57 0.382 0.03 (0.04 to 0.10)
Male 1,041 (64.54) 1,021 (63.30) 0.463 0.03 (0.04 to 0.09)
Body mass index, kg/m2 0.935 0.01 (0.06 to 0.08)
Normal 613 (38.00) 615 (38.13)
Underweight 69 (4.28) 73 (4.53)
Overweight 431 (57.72) 925 (57.35)
Logistic EuroSCORE, % 19.94  13.91 19.43  13.81 0.310 0.04 (0.03 to 0.11)
Main indication 0.445 0.06 (0.01 to 0.13)
Operative contraindication 217 (13.45) 216 (13.39)
High surgical risk 928 (57.53) 969 (60.07)
Frailty 386 (23.93) 353 (21.88)
Other 82 (5.08) 75 (4.65)
Nonelective procedure 134 (8.31) 140 (8.68) 0.705 0.01 (0.06 to 0.08)
Extracardiac history
Previous stroke/TIA 195 (12.09) 220 (13.64) 0.189 0.05 (0.02 to 0.11)
Peripheral vascular disease 809 (50.15) 804 (49.85) 0.860 0.01 (0.06 to 0.07)
Chronic pulmonary disease 408 (25.29) 405 (25.11) 0.903 <0.01 (0.06 to 0.07)
Diabetes mellitus 464 (28.77) 469 (29.08) 0.846 0.01 (0.06 to 0.07)
Renal failure 0.896 0.02 (0.04 to 0.09)
None 777 (48.17) 765 (47.43)
Moderate 622 (38.56) 642 (39.80)
Severe 172 (10.66) 164 (10.17)
Dialysis 42 (2.60) 42 (2.60)
Cardiac history
Cardiac symptoms 1,507 (93.43) 1,499 (92.93) 0.576 0.02 (0.05 to 0.09)
Coronary disease 1,021 (63.30) 1,006 (62.37) 0.585 0.02 (0.05 to 0.09)
Previous cardiac surgery 352 (21.82) 356 (22.07) 0.865 0.01 (0.06 to 0.07)
Previous permanent pacemaker 212 (13.14) 237 (14.69) 0.204 0.04 (0.02 to 0.11)
Previous SV arrhythmia 579 (35.90) 589 (36.52) 0.714 0.01 (0.05 to 0.08)
Ejection fraction 54.46  13.26 54.31  13.43 0.754 0.01 (0.06 to 0.08)
Pulmonary hypertension 0.727 0.04 (0.03 to 0.11)
None 480 (29.76) 492 (30.50)
Moderate 700 (43.40) 702 (43.52)
Severe 135 (8.37) 118 (7.32)
Nonmeasurable or NA 298 (18.47) 301 (18.66)
Aortic valve characteristics
Mean aortic gradient, mm Hg 46.29  14.40 46.02  14.35 0.593 0.02 (0.05 to 0.09)
Aortic valve area, cm2 0.71  0.23 0.72  0.21 0.568 0.02 (0.05 to 0.09)
Aortic annulus, mm 24.54  2.68 24.31  2.69 0.019 0.08 (0.01 to 0.16)
Moderate or severe AR 301 (22.40) 281 (20.81) 0.319 0.04 (0.04 to 0.11)
Prosthesis type <0.001 0.65 (0.58 to 0.72)
Self-expanding prosthesis 1074 (66.58) 574 (35.59)
Balloon-expandable prosthesis 539 (33.42) 1,039 (64.41)
Center volume 0.998 0.01 (0.06 to 0.07)
Low volume quartile 108 (6.70) 107 (6.63)
Low-intermediate volume quartile 262 (16.24) 262 (16.24)
High-intermediate volume quartile 327 (20.27) 331 (20.52)
High volume quartile 916 (56.79) 913 (56.60)
Time period 0.229 0.04 (0.03 to 0.11)
20132015 719 (44.58) 753 (46.68)
20162017 894 (55.42) 860 (53.32)
Values are mean  SD and n (%).
AR ¼ aortic regurgitation; NA ¼ not available; SV ¼ supraventricular; TIA ¼ transient ischemia attack.
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TABLE 2 Impact of Access Type on Outcome of the Matched Population
Nonfemoral
Access
(n ¼ 1,613)
Femoral
Access
(n ¼ 1,613)
Multivariate Analysis
OR* (95% CI) p Value
Procedural mortality 64 (3.97) 47 (2.91) 1.29 (0.871.94) 0.211
STEMI 4 (0.25) 3 (0.19) 0.81 (0.193.87) 0.774
Stroke 54 (3.35) 35 (2.17) 1.38 (0.882.19) 0.156
Annulus rupture 0 (0.00) 3 (0.19) 0.14 (0.001.62) 0.126
Aortic dissection 4 (0.25) 2 (0.12) 1.63 (0.3210.45) 0.564
Valve migration/embolization 16 (0.99) 11 (0.68) 1.09 (0.502.48) 0.833
Tamponade 24 (1.49) 18 (1.12) 1.38 (0.732.65) 0.321
Permanent pacemaker insertion 287 (17.79) 254 (15.75) 0.95 (0.781.16) 0.607
Pulmonary embolism 4 (0.25) 3 (0.19) 1.17 (0.275.57) 0.829
Renal failure 62 (3.84) 45 (2.79) 1.39 (0.922.11) 0.119
Renal dialysis 10 (0.62) 5 (0.31) 1.60 (0.545.34) 0.408
Major bleeding 138 (8.56) 121 (7.50) 1.06 (0.811.39) 0.676
Hemorrhagic shock 11 (0.68) 11 (0.68) 0.89 (0.372.14) 0.795
Unplanned vascular repairs 50 (3.10) 108 (6.70) 0.41 (0.290.59) <0.001
Major vascular complications 11 (0.68) 22 (1.36) 0.45 (0.210.93) 0.032
Surgery under bypass 3 (0.19) 6 (0.37) 0.41 (0.091.52) 0.183
Infectious complication 72 (4.46) 67 (4.15) 0.97 (0.681.39) 0.861
Values are n (%) unless otherwise indicated. *Odds ratio (OR) expressing the excess of risk of complication for
nonfemoral peripheral transcatheter aortic valve replacement after adjustment for prosthesis type and time
period.
CI ¼ conﬁdence interval; STEMI ¼ ST-segment elevation myocardial infarction.
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2735were the most frequent prostheses used in the FP
access group (64.41%), whereas self-expandable
prostheses were the most frequently used in the
n-FP access group (66.58%). Among the n-FP access
group, 911 (56.5%) patients underwent transcarotid
access and 702 (43.5%) patients underwent trans-
subclavian access.
IMPACT OF ACCESS SITE ON THE OUTCOME. Impact
of access type on outcomes in the unmatched popu-
lation is presented in Online Table 6. There were
more strokes (OR: 1.65; 95% CI: 1.22 to 2.20;
p ¼ 0.002), acute renal failures (OR: 1.39; 95% CI: 1.05
to 1.81; p ¼ 0.024), and major bleedings (OR: 1.22;
95% CI: 1.01 to 1.47; p ¼ 0.040), but less annulus
ruptures (OR: 0.12; 95% CI: 0.00 to 0.84; p ¼ 0.027),
major vascular complications (OR: 0.55; 95% CI: 0.28
to 0.95; p ¼ 0.031), and unplanned vascular repairs
(OR: 0.45; 95% CI: 0.33 to 0.59; p < 0.001) in the
n-FP group.
Among the 1,613 matched n-FP cases, mean post-
procedural length of stay was signiﬁcantly higher in
the n-FP group (8.86 days vs. 7.98 days; p ¼ 0.006).
The procedural mortality rate was 3.97% versus 2.91%
in the FP group (p ¼ 0.211); the ST-segment elevation
myocardial infarction rate was 0.25% versus 0.19%
(p ¼ 0.774), the stroke rate was 3.35% versus 2.17%
(p ¼ 0.156), the major vascular complications rate was
0.68% versus 1.36% (p ¼ 0.032), and unplanned
vascular repairs occurred in 3.10% of cases versus
6.70% of cases (p < 0.001). Compared with FP access,
n-FP access was not associated with increased pro-
cedural mortality (OR: 1.29; 95% CI: 0.87 to 1.94;
p ¼ 0.211) or associated with an increased risk of
stroke (OR: 1.38; 95% CI: 0.88 to 2.19; p ¼ 0.156). As
shown in Table 2, there was no difference in the rate
of any complications according to the access site in
the matched population, except for a 2-fold lower rate
of major vascular complications (OR: 0.45; 95% CI:
0.21 to 0.93; p ¼ 0.032) and unplanned vascular re-
pairs (OR: 0.41; 95% CI: 0.29 to 0.59; p < 0.001) in the
n-FP access group. In multivariate logistic regression,
FP access was an independent predictor of major
vascular complications (Online Table 7).
In the n-FP group, unmatched comparison be-
tween the transcarotid and trans-subclavian accesses
(Online Tables 8 and 9) showed no difference in the
stroke rate (3.62% and 2.99%, respectively;
p ¼ 0.485). There were more renal failures (OR: 1.78;
95% CI: 1.03 to 3.16; p ¼ 0039) and major bleedings
(OR: 1.82; 95% CI: 1.25 to 2.68; p ¼ 0.002) but less
hemorrhagic shocks (OR: 0.26; 95% CI: 0.06 to 0.91;
p ¼ 0.035) and major vascular complications (OR:
0.21; 0.04 to 0.80; p ¼ 0.021).Per-per iod subana lys i s . Over the 5-year study
period, the distribution of TAVR accesses signiﬁ-
cantly evolved (p < 0.001). The rate of FP TAVR
increased from 79.95% in 2013 to 2015 to 89.12% in
2016 to 2017, with a massive decrease in central TAVR
(i.e., transapical and transaortic) from 11.99% to
3.76%, whereas the rate of n-FP TAVR remained sta-
ble from 7.66% to 6.62% (Figure 3). Distribution of
prostheses types across the 2 study periods are shown
in Online Table 10.
In the total population (n ¼ 21,611), mean post-
procedural length of stay decreased in both groups
(9.99 to 7.96 days in the n-FP group; p < 0.001; and
8.71 to 6.80 days in the FP group; p < 0.001). The
procedural mortality rate decreased from 3.76% to
2.36% (p < 0.001), and the major vascular complica-
tions rate decreased signiﬁcantly in the total popu-
lation from 1.44% to 1.02% (p ¼ 0.005). There was a
nonsigniﬁcant decrease in stroke rate in the total
population from 2.06% to 1.81% (p ¼ 0.173).
When considering the 2016 to 2017 period sepa-
rately, there was no difference in the rate of any
complications according to the access site in the
matched population, except for a 4-fold lower rate of
major vascular complications (OR: 0.26; 95% CI: 0.07
to 0.78; p ¼ 0.015) and a 2-fold lower rate of un-
planned vascular repairs (OR: 0.47; 95% CI: 0.28 to
0.77; p ¼ 0.002) in the n-FP access group. The
FIGURE 3 Evolution of the Distribution of Different Accesses for
TAVR From 2012 to 2017
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Among the 27,997 TAVR recipients included in the FRANCE-TAVI Registry
between January 2013 and December 2017: femoral peripheral refers to
transfemoral TAVR, nonfemoral peripheral includes trans-subclavian and
transcarotid TAVR, central includes transapical and trans aortic TAVR, and
other represent all the accesses not mentioned or not labeled. Abbrevia-
tions as in Figure 1.
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2736complete per-period subanalysis is shown in Online
Table 11.
Per-center volume subanalysis. In high-intermediate/
high volume centers, there was no difference in the
rate of complications according to the access site in
the matched population, except for a 3-fold lower rate
of major vascular complications (OR: 0.35; 0.13 to
0.84; p ¼ 0.018) and a 2-fold lower rate of unplanned
vascular repairs (OR: 0.44; 95% CI: 0.29 to 0.66;
p < 0.001) in the n-FP access group. The per-center
volume subanalysis is shown in Online Table 12.DISCUSSION
In this large multicentric study that included all
peripheral vascular TAVRs performed in France be-
tween 2013 and 2017, after a pre-speciﬁed propensity-
based matching, the complications rate was low and
similar between n-FP and FP TAVR, except for a
2-fold lower rate of major vascular complications or
unplanned vascular repairs in the n-FP TAVR group
(Central Illustration). The results were consistent over
the 2 study periods, despite a reduction in procedural
mortality, stroke, major vascular complications, and
unplanned vascular repairs rates. The comparisons of
outcomes provided similar results in intermediate-
high/high volume centers.
TAVR has widely developed during the last
several years, shifting from a technique that was
solely used in patients who were ineligible for sur-
gery, to a procedure that can now be considered in a
large subset of patients, including those at lower
risk. More recent studies have shown similar or even
lower rates of death, stroke, or rehospitalization,
compared with surgery, including among patients at
low surgical risk (17,18). FP access is the current gold
standard for TAVR procedures and is the ﬁrst-line
access site considered when TAVR is envisaged.
Current guidelines state the feasibility of FP access is
one of the key features that need to be assessed
before choosing between TAVR and surgical valve
replacement (1,7). However, despite great improve-
ment in TAVR techniques and device proﬁles,
approximately 10% to 15% of patients are still denied
FP access due to unfavorable anatomy (6). In cases of
intermediate-risk patients, European guidelines
recommend that a surgical option be reconsidered
(1). However, n-FP accesses have emerged as alter-
natives to FP, although no dedicated devices have
been made for n-FP access (8,9,18). Those n-FP ac-
cesses have not been accurately compared with
surgery or FP TAVR.
From an organizational point of view, n-FP TAVR is
more invasive and more demanding than FP TAVR, in
which procedural duration has decreased with time
and general anesthesia can now be avoided in expe-
rienced centers (19). This led to the development of
minimalistic TAVR with a shorter length of hospital
stay and a simpliﬁcation of procedure organization
(20). Regarding safety and outcome, comparison of
access types in observational studies has been limited
by the great variability among patients who undergo
different accesses, with patients with more severe
disease undergoing n-FP TAVR. In our study, we
performed propensity-based matching to allow an
CENTRAL ILLUSTRATION Femoral or Nonfemoral Peripheral TAVR
Beurtheret, S. et al. J Am Coll Cardiol. 2019;74(22):2728–39.
Comparison of patients from the FRANCE TAVI (French Transcatheter Aortic Valve Implantation) registry (2013 to 2017) who underwent transcatheter aortic valve
replacement (TAVR), either through a femoral peripheral or a nonfemoral peripheral (n-FP) access. After propensity scorebased matching, both groups had similar
results. Bold indicates signiﬁcant difference between the 2 groups. *Odds ratio (OR) expressing the excess of risk of complication for n-FP TAVR, after adjustment on
prosthesis type and time period. PM ¼ pacemaker; STEMI ¼ ST-segment elevation myocardial infarction.
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PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: n-FP arterial access for
TAVR is associated with a lower risk of major vascular
complications than femoral access and otherwise
similar procedural outcomes.
TRANSLATIONAL OUTLOOK: The outcomes of
patients with aortic stenosis who undergo TAVR with
nonfemoral peripheral access should be compared
with those managed with surgical aortic valve
replacement.
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observe any difference in procedural mortality or
complication rates between FP and n-FP access, but
n-FP access was associated with a lower rate of major
vascular complications and unplanned vascular re-
pairs compared with FP access. This conﬁrmed the
ﬁndings of previous studies (21,22).
The absence of increased risk of disabling stroke in
n-FP TAVR was another major ﬁnding in our study.
Despite all the advances in TAVR techniques, stroke
remained the most feared complication, with evi-
dence of silent and apparent microembolism in 50%
to 94% of patients within the ﬁrst month after TAVR
(22,23). Cerebrovascular events were mainly attrib-
uted to the dislodgment of calciﬁed debris and/or
aortic valve tissue during the TAVR procedure (24).
This hypothesis was further supported by the
reduction of cerebral lesion volumes in diffusion-
weighted magnetic resonance imaging in patients
who underwent TAVR with embolic protection de-
vices (25). In the case of n-FP access (mainly trans-
carotid), a speciﬁc mechanism for cerebrovascular
events could be imagined, related to local complica-
tions and to the transient reduction in cerebral blood
ﬂow during the procedure. This theoretical increase
in stroke rate was not observed in our study, which
further supported a wider use of this access when FP
access was deemed not feasible during the pre-
operative workup.
Improvements in device performance and operator
experience led to a decrease in length of stay after
the procedure and a reduction in the rates of death,
stroke, major vascular complications, and unplanned
vascular repairs. However, comparison between FP
and n-FP access provided similar results in both
study periods, regardless of volume center size. In
particular, n-FP access remained associated with a
lower rate of unplanned vascular repairs and a lower
rate of major vascular complications, which high-
lighted the necessity of considering n-FP access in
complex FP cases. Further studies and speciﬁc scores
are needed to identify the patients at higher risk for
major vascular complications or unplanned vascular
repairs who would beneﬁt from this alternative
access.
STUDY LIMITATIONS. Despite the large number of
patients included and the involvement of several
centers in the study, several limitations have to be
acknowledged. First, although propensity matching
was performed to reduce indication bias, which
allowed a more reliable comparison of patients ac-
cording to the access site, the results had to beanalyzed with caution because of the nonrandomized
nature of the study. Some differences persisted be-
tween the groups. In particular, the most frequent
prosthesis type differed according to the access site
because we chose to match on only the baseline
characteristics of the patients. However, the pros-
thesis type was adjusted in the multivariate regres-
sion model and was not likely to inﬂuence the results.
Second, for the sake of matching, we excluded pa-
tients with incomplete data. However, unadjusted
comparison between n-FP and FP approaches among
excluded patients with incomplete data showed
similar results, indicating that this did not introduce
any bias. Third, only symptomatic strokes were re-
ported, and there was no systematic cerebral imaging.
Therefore, the rate of silent cerebrovascular embo-
lisms was not assessed. However, the impact of these
silent microembolisms remains to be determined.
CONCLUSIONS
Among peripheral vascular TAVR, after a pre-
speciﬁed, propensity-based matching, n-FP and FP
TAVR provided similar results and a similar safety
proﬁle, except for a 2-fold lower rate of major
vascular complications or unplanned vascular repairs
in the n-FP TAVR group. Although FP access remains
the ﬁrst choice in TAVR, n-FP TAVR may be a safe
alternative when femoral access risk is considered too
high and may be favored over surgery in patients who
are deemed ineligible for FP TAVR.
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